ABBOTT LABORATORIES·4

Sep 13, 5:24 PM ET

Ford Robert B 4

4 · ABBOTT LABORATORIES · Filed Sep 13, 2024

Insider Transaction Report

Form 4
Period: 2024-09-12
Ford Robert B
DirectorCHAIRMAN AND CEO
Transactions
  • Exercise/Conversion

    Common shares without par value

    2024-09-12$47.00/sh+127,436$5,989,492347,495 total
  • Exercise/Conversion

    Common shares without par value

    2024-09-12$48.90/sh+14,243$696,483361,738 total
  • Sale

    Common shares without par value

    2024-09-12$116.04/sh80,299$9,317,896281,439 total
  • Sale

    Common shares without par value

    2024-09-12$116.90/sh61,380$7,175,322220,059 total
  • Exercise/Conversion

    Option (right to buy)

    2024-09-12127,4360 total
    Exercise: $47.00From: 2018-02-20Exp: 2025-02-19Common Shares (127,436 underlying)
  • Exercise/Conversion

    Option (right to buy)

    2024-09-1214,2430 total
    Exercise: $48.90From: 2018-06-01Exp: 2025-05-31Common Shares (14,243 underlying)
Holdings
  • Common shares without par value

    (indirect: By Trust)
    197,403
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.58 to $116.54, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.58 to $117.29, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
  • [F4]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file
  • 4
    form4-09132024_090935.xmlPrimary